YmAbs Therapeutics (YMAB)
(Delayed Data from NSDQ)
$4.53 USD
+0.06 (1.34%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $4.52 -0.01 (-0.22%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth C Momentum D VGM
Fundamental Charts
About Dividend Yield (TTM)
Y-mAbs Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
YMAB 4.53 +0.06(1.34%)
Will YMAB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for YMAB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for YMAB
YmAbs Therapeutics (YMAB) Upgraded to Buy: Here's What You Should Know
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates
YMAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Lags Revenue Estimates
Anika Therapeutics (ANIK) Reports Q1 Loss, Misses Revenue Estimates
Qiagen (QGEN) Q1 Earnings and Revenues Surpass Estimates
Other News for YMAB
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
JonesTrading Keeps Their Buy Rating on Y-Mabs Therapeutics (YMAB)